GlassScriptPhysician profile
Yifan Tu
NPI 1447405899
$63,546.66
in general payments reported to CMS, 2019-2025
80 companies · $16K in 2025
The $16K reported for 2025 was more than what 92% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $7,631 · 2020: $236 · 2021: $3,714 · 2022: $3,231 · 2023: $11K · 2024: $22K · 2025: $16K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $30K · Food and Beverage: $14K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,750 · Travel and Lodging: $2,024 · Education: $29.97.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $29,867.00 |
| Food and Beverage | $14,063.53 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,750.00 |
| Travel and Lodging | $2,024.35 |
| Education | $29.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $20,775.89 | 2019-2025 | Tagrisso, Calquence, Imfinzi |
| Novartis Pharmaceuticals Corporation | $7,683.15 | 2019-2025 | Kisqali, Piqray |
| Avyxa Pharma, LLC | $4,144.89 | 2025 | |
| Daiichi Sankyo INC. | $4,030.64 | 2021-2025 | Enhertu, Datroway, Injectafer |
| Regeneron Pharmaceuticals, INC. | $4,002.17 | 2023-2025 | Libtayo |
| Sobi, INC | $3,540.12 | 2022-2025 | |
| Genzyme Corporation | $2,417.09 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $2,044.49 | 2019-2025 | Opdualag, Opdivo, Reblozyl |
| Amgen INC. | $1,225.00 | 2019-2025 | Nplate, Xgeva, Vectibix |
| Janssen Biotech, INC. | $1,039.96 | 2019-2025 | Darzalex, Tecvayli, Carvykti |
| Merck Sharp & Dohme LLC | $695.71 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Genentech USA, INC. | $695.31 | 2022-2025 | Lunsumio, Polivy, Tecentriq |
| Eisai INC. | $637.47 | 2020-2025 | |
| Gilead Sciences, INC. | $635.65 | 2021-2025 | Trodelvy |
| Regeneron Healthcare Solutions, INC. | $576.68 | 2021-2025 | Libtayo |
Show all 80 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $540.59 | 2021-2025 | |
| Celgene Corporation | $502.07 | 2022-2025 | Reblozyl, Pomalyst, Breyanzi |
| Abbvie INC. | $497.74 | 2019-2025 | Venclexta |
| Tempus Ai, INC | $473.63 | 2024-2025 | Xt Cdx |
| Emd Serono, INC. | $455.10 | 2021-2025 | Bavencio |
| Glaxosmithkline, LLC. | $409.15 | 2021-2025 | Ojjaara, Jemperli, Zejula |
| Incyte Corporation | $395.80 | 2020-2025 | Jakafi, Monjuvi, Pemazyre |
| Seagen INC. | $306.69 | 2021-2023 | Tukysa, Adcetris, Padcev |
| Adaptive Biotechnologies Corporation | $288.06 | 2021-2023 | Clonoseq |
| Genentech, INC. | $279.90 | 2023-2024 | Tecentriq, Lunsumio, Alecensa |
| Lilly USA, LLC | $250.23 | 2021-2025 | Jaypirca, Verzenio, Retevmo |
| Takeda Pharmaceuticals U.S.A., INC. | $244.65 | 2023-2025 | Iclusig, Alunbrig, Fruzaqla |
| Astellas Pharma US INC | $234.91 | 2023-2025 | Vyloy, Padcev, Xtandi |
| Myriad Genetic Laboratories, INC. | $223.06 | 2021-2023 | Myrisk |
| Exelixis INC. | $220.80 | 2019-2025 | Cabometyx |
| Pharmacyclics LLC, An Abbvie Company | $219.68 | 2022-2023 | Epkinly, Imbruvica |
| Intera Oncology, INC | $206.19 | 2024-2025 | Intera |
| Genmab U.S., INC. | $196.86 | 2023-2025 | Epkinly |
| Bayer Healthcare Pharmaceuticals INC. | $177.63 | 2021-2025 | |
| Astellas Pharma Global Development | $163.70 | 2023-2025 | Xospata, Padcev |
| Cti Biopharma Corp. | $160.89 | 2023 | Vonjo |
| Karyopharm Therapeutics INC. | $158.83 | 2022-2025 | Xpovio |
| Blueprint Medicines Corporation | $155.00 | 2021-2023 | Ayvakit |
| Tersera Therapeutics LLC | $151.41 | 2022-2025 | Zoladex, Xermelo |
| Servier Pharmaceuticals LLC | $147.30 | 2021-2025 | |
| Jazz Pharmaceuticals INC. | $142.60 | 2022-2025 | |
| Array Biopharma INC | $135.41 | 2022-2025 | Braftovi, Lorbrena, Mektovi |
| Stemline Therapeutics INC. | $128.23 | 2023-2025 | Orserdu, Elzonris |
| Boehringer Ingelheim Pharmaceuticals, INC. | $123.36 | 2022-2024 | Gilotrif |
| Pharmaessentia USA Corporation | $122.93 | 2023-2024 | Besremi |
| Puma Biotechnology, INC. | $119.92 | 2020-2025 | |
| Alexion Pharmaceuticals, INC. | $118.58 | 2019-2025 | Ultomiris |
| Rigel Pharmaceuticals, INC. | $101.69 | 2021-2024 | Rezlidhia, Tavalisse |
| Ipsen Biopharmaceuticals, INC | $97.94 | 2023-2025 | Onivyde, Tazverik, Somatuline Depot |
| Taiho Oncology, INC. | $85.45 | 2021-2025 | |
| Kite Pharma, INC. | $84.86 | 2022-2023 | Yescarta |
| Adc Therapeutics America, INC. | $75.84 | 2021-2025 | |
| Aveo Pharmaceuticals, INC. | $74.77 | 2021-2025 | Fotivda |
| Beone Medicines USA, INC. | $71.90 | 2025 | Tevimbra, Brukinsa |
| Recordati_rare_diseases_inc. | $69.72 | 2025 | Enjaymo, Sylvant |
| Geron Corporation | $66.07 | 2025 | Rytelo |
| Beigene USA, INC. | $60.17 | 2022-2025 | Tevimbra |
| Emmaus Medical, INC. | $50.05 | 2023-2024 | Endari |
| Mirati Therapeutics, INC. | $47.68 | 2023-2024 | Krazati |
| Morphosys, US INC. | $46.73 | 2021-2022 | |
| Springworks Therapeutics, INC. | $45.55 | 2024-2025 | Ogsiveo |
| Kyowa Kirin, INC. | $41.58 | 2021-2023 | Poteligeo |
| Aimmune Therapeutics, INC. | $38.43 | 2025 | Zenpep |
| Sumitomo Pharma America, INC. | $36.61 | 2023-2024 | Orgovyx |
| Global Blood Therapeutics, INC. | $32.81 | 2021-2022 | |
| Coherus Oncology, INC. | $31.27 | 2022-2024 | |
| Epizyme, INC. | $29.86 | 2022 | |
| Azurity Pharmaceuticals, INC. | $24.89 | 2025 | Danziten |
| G1 Therapeutics, INC. | $23.95 | 2022 | |
| Menarini Silicon Biosystems, INC. | $23.78 | 2024 | |
| Pinnacle Biologics, INC | $22.59 | 2025 | Photofrin |
| Pharmacosmos Therapeutics INC. | $22.39 | 2022 | |
| Apellis Pharmaceuticals, INC. | $21.21 | 2023 | Empaveli |
| Blue Earth Diagnostics | $20.59 | 2021 | |
| Syndax Pharmaceuticals, INC. | $19.89 | 2025 | |
| Myovant Sciences INC. | $18.99 | 2021 | |
| Spectrum Pharmaceuticals INC. | $16.53 | 2024 | Rolvedon |
| Foundation Medicine, INC. | $16.46 | 2023 | |
| Melinta Therapeutics, LLC | $16.29 | 2024 | Kimyrsa, Rezzayo |
| Caris Mpi, INC. | $15.00 | 2025 | Mi Cancer Seek |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$1,740.96 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yifan Tu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.